Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 20 | 2018 | 21 | 5.650 |
Why?
|
| Quality of Life | 11 | 2018 | 26 | 1.690 |
Why?
|
| Adult | 17 | 2018 | 551 | 1.160 |
Why?
|
| Female | 19 | 2018 | 971 | 1.120 |
Why?
|
| Middle Aged | 16 | 2018 | 488 | 1.100 |
Why?
|
| Humans | 22 | 2018 | 1892 | 1.020 |
Why?
|
| Severity of Illness Index | 11 | 2018 | 59 | 1.020 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2017 | 7 | 0.940 |
Why?
|
| Male | 15 | 2018 | 1041 | 0.910 |
Why?
|
| Health Status | 4 | 2017 | 12 | 0.900 |
Why?
|
| Surveys and Questionnaires | 7 | 2017 | 95 | 0.880 |
Why?
|
| Fatigue | 2 | 2018 | 6 | 0.700 |
Why?
|
| Lupus Nephritis | 1 | 2017 | 1 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 5 | 0.540 |
Why?
|
| Rheumatologists | 1 | 2017 | 4 | 0.540 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 3 | 0.540 |
Why?
|
| Biological Products | 1 | 2016 | 1 | 0.510 |
Why?
|
| Pain | 4 | 2018 | 25 | 0.480 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 60 | 0.450 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2004 | 7 | 0.440 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 2 | 0.440 |
Why?
|
| Psychometrics | 5 | 2017 | 17 | 0.410 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 2 | 0.400 |
Why?
|
| Emotions | 3 | 2017 | 5 | 0.380 |
Why?
|
| Aged | 4 | 2017 | 414 | 0.280 |
Why?
|
| Linear Models | 4 | 2018 | 18 | 0.250 |
Why?
|
| Self Report | 3 | 2017 | 12 | 0.250 |
Why?
|
| Young Adult | 3 | 2016 | 142 | 0.250 |
Why?
|
| Body Image | 2 | 2017 | 2 | 0.250 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 80 | 0.240 |
Why?
|
| Canada | 2 | 2016 | 6 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 22 | 0.240 |
Why?
|
| Depressive Disorder | 2 | 2018 | 17 | 0.230 |
Why?
|
| Cross-Cultural Comparison | 2 | 2016 | 4 | 0.230 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 2 | 0.220 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 5 | 0.220 |
Why?
|
| Chlamydia trachomatis | 1 | 2004 | 3 | 0.220 |
Why?
|
| Treatment Outcome | 4 | 2016 | 118 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2004 | 4 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 36 | 0.220 |
Why?
|
| Adolescent | 2 | 2016 | 187 | 0.220 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2004 | 1 | 0.210 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 63 | 0.210 |
Why?
|
| Pain Measurement | 4 | 2017 | 27 | 0.210 |
Why?
|
| Factor Analysis, Statistical | 3 | 2017 | 8 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 2 | 2017 | 2 | 0.190 |
Why?
|
| Depression | 2 | 2013 | 27 | 0.190 |
Why?
|
| Stress, Psychological | 2 | 2018 | 11 | 0.170 |
Why?
|
| Time Factors | 2 | 2017 | 143 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 14 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 19 | 0.150 |
Why?
|
| Chicago | 1 | 2018 | 56 | 0.150 |
Why?
|
| Mental Health | 1 | 2017 | 5 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 4 | 0.140 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 2 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2017 | 7 | 0.140 |
Why?
|
| Illinois | 1 | 2017 | 14 | 0.130 |
Why?
|
| Sleep | 1 | 2017 | 36 | 0.130 |
Why?
|
| Philippines | 2 | 2017 | 2 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 2 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 41 | 0.120 |
Why?
|
| United States | 1 | 2016 | 155 | 0.120 |
Why?
|
| Software | 1 | 2015 | 6 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 60 | 0.120 |
Why?
|
| Physicians | 1 | 2015 | 12 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2014 | 1 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 3 | 0.110 |
Why?
|
| Rheumatology | 1 | 2014 | 5 | 0.110 |
Why?
|
| Goals | 1 | 2014 | 5 | 0.110 |
Why?
|
| Language | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cognition | 1 | 2014 | 73 | 0.110 |
Why?
|
| Interferon Type I | 1 | 2013 | 1 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2013 | 1 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 3 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 19 | 0.100 |
Why?
|
| California | 3 | 2017 | 9 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 107 | 0.070 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 5 | 0.070 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 19 | 0.070 |
Why?
|
| Arthralgia | 1 | 2008 | 12 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 4 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2004 | 15 | 0.060 |
Why?
|
| Comorbidity | 1 | 2004 | 27 | 0.060 |
Why?
|
| Prevalence | 1 | 2004 | 26 | 0.060 |
Why?
|
| Hypertension | 1 | 2004 | 10 | 0.060 |
Why?
|
| Pregnancy | 1 | 2004 | 44 | 0.060 |
Why?
|
| Lactones | 1 | 2004 | 1 | 0.050 |
Why?
|
| Methotrexate | 1 | 2004 | 1 | 0.050 |
Why?
|
| Sulfasalazine | 1 | 2004 | 1 | 0.050 |
Why?
|
| Sulfones | 1 | 2004 | 1 | 0.050 |
Why?
|
| Synovial Fluid | 1 | 2004 | 3 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 13 | 0.050 |
Why?
|
| Doxycycline | 1 | 2004 | 4 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 8 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 16 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2004 | 1 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 4 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 28 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 42 | 0.050 |
Why?
|
| Social Class | 1 | 2017 | 4 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 1 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 8 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 9 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 51 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2016 | 4 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2014 | 5 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2013 | 3 | 0.030 |
Why?
|
| DNA | 1 | 2013 | 21 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 43 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 17 | 0.030 |
Why?
|
| Mexican Americans | 1 | 2011 | 1 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 5 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 10 | 0.020 |
Why?
|
| Knee Joint | 1 | 2008 | 15 | 0.020 |
Why?
|